Developing a technology to enable the rapid diagnosis of urinary tract infection (UTI)

JEAYS-WARD, Katherine, WELLS, Oliver, MCCARTHY, Avril, MORRIS, Nicola, JACOBSON, Kim, HAY, Alastair, BARNETT, Jackie, PIANO, Martina, LUXTON, Richard, KIELY, Janice, HAYWARD, Gail, MICCICHE, Angelo, LOVERING, Andrew, LANGLEY, Joe <http://orcid.org/0000-0002-9770-8720>, PARTRIDGE, Rebecca, ANKENY, Ursula, SKEWS, Rachel, YANG, Yaling, DAHER, Shahd and DRAKE, Marcus

Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/25333/

This document is the author deposited version. You are advised to consult the publisher’s version if you wish to cite from it.

Published version


Copyright and re-use policy

See http://shura.shu.ac.uk/information.html
Developing a technology to enable the rapid diagnosis of urinary tract infection (UTI)

Katherine Jeays-Ward¹, Oliver Wells¹, Avril McCarthy¹, Nicola Morris⁴, Kim Jacobson¹, Alastair Hay¹, Jackie Barnett¹, Martina Piano³, Richard Luxton⁴, Janice Kiely⁴, Gail Hayward⁵, Angels Misciche³, Andrew Lovering¹, Joe Langleys, Rebecca Partridge⁴, Ursula Ankeny⁴, Rachel Skews¹, Yaling Yang⁵, Shahd Daher⁵, Marcus Drake²

¹NIHR Devices for Dignity MedTech Co-operative, Sheffield Teaching Hospitals NHS Foundation Trust, ²North Bristol NHS Trust, ³University of Bristol, ⁴University of the West of England, ⁵NIHR Oxford MedTech and In vitro diagnostic Co-operative, University of Oxford, ⁶Sheffield Hallam University

Community acquired UTI is common, and causes considerable morbidity and health expense. The presence of sufficient numbers of bacterial organisms and an inflammatory reaction indicates UTI. Approximately 90% are due to one of three organisms (E.coli, Klebsiella, Proteus). Testing for UTI includes urinary dipstick testing, which is rapid but prone to false positives. Alternatively, urine samples may be cultured, but this requires laboratory facilities and technical staff, and is slow and expensive. Often patients are treated on symptoms alone, and this risks over-treatment, i.e. some patients erroneously thought to have UTI receiving antibiotics inappropriately. GP concerns (inappropriate antibiotics, costs) and patient concerns (delayed treatment) make UTI management a significant issue. Internationally, emerging multi-resistant organisms mandates major public health focus to reduce inappropriate prescribing.

A UTI point-of-care (POC) diagnostic has been identified as the highest priority diagnostic for GPs. We have formed a collaborative team to adapt and exploit a technology developed by the University of the West of England that can be used by GPs, community nurses, pharmacists and others to identify and quantify the presence of the three species of bacteria that are commonly present in urinary tract infections; diagnosis of UTI is being confirmed by the presence of an additional biomarker.

This poster introduces some of the factors we are considering to ensure the diagnostic rigour, clinical applicability, and user-centric design of this product, and the exploitation and adoption routes that we are exploring concurrently with the technology development.

Product Development

Is it needed?
Does it work?
Can we make it?

Commercial Viability

Can we distribute to users?
Can we make enough?
Cost and price?

Will it be used in Practice?

Capability
Opportunity
Motivation

Successful commercially viable product with tangible benefits to patients and healthcare systems.